Compass Therapeutics, Inc.
A clinical-stage biopharmaceutical company developing antibody-based therapies for cancer and autoimmune disease, working on programs such as bispecific antibodies and antibody-drug conjugates. It grew out of Boston's biotech ecosystem, founded by drug-development scientists in the early 2010s to build a pipeline of novel antibody medicines aimed at solid tumors. The company takes its name from the guiding idea of using antibodies to "point" the immune system, like a compass, toward cancer cells — a naming quirk that frames its whole mission.
Granted 250.0K
Granted 125.0K
Granted 62.5K · Bought 15.0K
Granted 150.0K · Bought 25.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Schuetz Thomas J.CHIEF EXECUTIVE OFFICER, Director · 4 transactions | +1.9% | 6.60M | 250.0K | — | — |
| Shin BarryCFO · 1 transaction | +31.3% | 525.0K | 125.0K | — | — |
| Lerner NeilChief Accounting Officer · 2 transactions | +24.2% | 397.5K | 62.5K | 15.0K | — |
| Anderman JonathanGeneral Counsel · 2 transactions | +833.3% | 196.0K | 150.0K | 25.0K | — |
Select a row to see that insider’s individual transactions.
Net open-market activity over the last year: +40.0K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.